Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 21:86:103374.
doi: 10.1016/j.eclinm.2025.103374. eCollection 2025 Aug.

The effect of tranexamic acid on blood coagulation in primary total hip arthroplasty using rotational thromboelastometry: a randomized controlled trial

Uzung Yoon  1 , David Beausang  1 , Elia Elia  2 , Marc Torjman  1 , Jeffrey Mojica  1 , James Purtill  3 , David Nazarian  3 , P Maxwell Courtney  3 , Yoogoo Kang  1
Affiliations

The effect of tranexamic acid on blood coagulation in primary total hip arthroplasty using rotational thromboelastometry: a randomized controlled trial

Uzung Yoon et al. EClinicalMedicine. .

Abstract

Background: Tranexamic acid (TXA), is commonly administered prophylactically to reduce blood loss in patients undergoing total hip arthroplasty (THA). However, its effect has never been studied. We hypothesized that no difference exists in the degree of fibrinolysis and blood loss between patients receiving prophylactic TXA and placebo.

Methods: This double-blinded randomized-controlled trial included 50 patients undergoing primary THA in 2021-2023. Clinicaltrials.gov (NCT03897621). Rotational-thromboelastometry (ROTEM) were performed to test blood coagulability using non citrated whole blood (NATEM) and blood treated with TXA (T-APTEM). The intervention group received TXA intravenously. The placebo group received 0.9% sodium chloride solution. The primary outcome measure was to quantitate the degree of fibrinolysis measured by maximum lysis (ML) demonstrated by ROTEM variables. Fibrinolysis was defined as ML (maximum lysis) > 15% within 1 h of testing.

Findings: Blood coagulability tested by ROTEM was within the normal range in all patients, and no difference was found between the TXA group and placebo group.NATEM and T-APTEM variables were similar in both groups and no patient developed fibrinolysis during the entire perioperative phases. At baseline, T-APTEM, compared with NATEM, showed shorter CT (746 ± 265 vs. 991 ± 237 p < 0.05) and greater ML (1.9 ± 2.2 vs. 0.8 ± 1, p < 0.05), suggesting some degree of acceleration of coagulation. Postoperatively, blood coagulability showed a tendency of acceleration with shorter CT (689 ± 188 vs. 828 ± 163, p < 0.05) and CFT (258 ± 101 vs. 293 ± 87 p < 0.05) and increased A10 (41 ± 9 vs. 38 ± 8, p < 0.05). Clinical outcomes, including blood loss, hematologic variables, and coagulation profile were similar between the two groups.

Interpretation: Normal range of blood coagulability in all patients, no significant differences between NATEM and T-APTEM variables, and similar clinical outcome between the two groups suggest that there is no definitive medical indication for TXA administration in patients undergoing THA without a preexisting fibrinolytic condition. Monitoring blood coagulability using ROTEM may be useful in guiding selective administration of TXA in high-risk patients.

Funding: Department of Anesthesiology funding, Thomas Jefferson University Hospital. Support was provided solely from institutional and/or departmental sources.

Keywords: Antifibrinolytic; Coagulation; Fibrinolysis; Rotational thromboelastometry; Total hip arthroplasty; Tranexamic acid.

PubMed Disclaimer

Conflict of interest statement

UY: Leadership–International Liver Transplantation Society. MT: Grants–RTM Vital Signs LLC Grant, NIH SBIR Grant. Pending Patents–Non invasive respiratory monitor With Jefferson and RTM Vital Signs LLC. JM: Support for attending meetings–Thomas Jefferson University. Leadership–ASRA Perioperative Special Interest Group – Co-Chair (Unpaid).

Figures

Fig. 1
Fig. 1
Flow diagram of the study.
Fig. 2
Fig. 2
Variables and measurements. By ROTEM delta. Used with permission by Werfen. Source: ROTEM operator training manual.
See this image and copyright information in PMC

References

    1. Fillingham Y.A., Ramkumar D.B., Jevsevar D.S., et al. The efficacy of tranexamic acid in total hip arthroplasty: a network meta-analysis. J Arthroplasty. 2018;33:3083–3089. - PubMed
    1. Sentilhes L., Sénat M.V., Le Lous M., et al. Tranexamic acid for the prevention of blood loss after cesarean delivery. N Engl J Med. 2021;384:1623–1634. - PubMed
    1. Devereaux P.J., Marcucci M., Painter T.W., et al. POISE-3 Investigators Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med. 2022;386:1986–1997. - PubMed
    1. Roberts I., Shakur H., Coats T., et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17:1–79. - PMC - PubMed
    1. Rahmani R., Singleton A., Fulton Z., et al. Tranexamic acid dosing strategies and blood loss reduction in multilevel spine surgery: a systematic review and network meta-analysis: tranexamic acid for multilevel spine surgery. N Am Spine Soc J. 2021;8 - PMC - PubMed

Associated data

LinkOut - more resources